These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 26261096

  • 1. Differential temporal effects of sclerostin antibody and parathyroid hormone on cancellous and cortical bone and quantitative differences in effects on the osteoblast lineage in young intact rats.
    Ominsky MS, Brown DL, Van G, Cordover D, Pacheco E, Frazier E, Cherepow L, Higgins-Garn M, Aguirre JI, Wronski TJ, Stolina M, Zhou L, Pyrah I, Boyce RW.
    Bone; 2015 Dec; 81():380-391. PubMed ID: 26261096
    [Abstract] [Full Text] [Related]

  • 2. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
    Taylor S, Ominsky MS, Hu R, Pacheco E, He YD, Brown DL, Aguirre JI, Wronski TJ, Buntich S, Afshari CA, Pyrah I, Nioi P, Boyce RW.
    Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
    [Abstract] [Full Text] [Related]

  • 3. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M, Dwyer D, Niu QT, Villasenor KS, Kurimoto P, Grisanti M, Han CY, Liu M, Li X, Ominsky MS, Ke HZ, Kostenuik PJ.
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [Abstract] [Full Text] [Related]

  • 4. The effects of sclerostin antibody plus parathyroid hormone (1-34) on bone formation in ovariectomized rats.
    Wu J, Cai XH, Qin XX, Liu YX.
    Z Gerontol Geriatr; 2018 Jul; 51(5):550-556. PubMed ID: 28364259
    [Abstract] [Full Text] [Related]

  • 5. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.
    Ominsky MS, Niu QT, Li C, Li X, Ke HZ.
    J Bone Miner Res; 2014 Jun; 29(6):1424-30. PubMed ID: 24967455
    [Abstract] [Full Text] [Related]

  • 6. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X, Ominsky MS, Villasenor KS, Niu QT, Asuncion FJ, Xia X, Grisanti M, Wronski TJ, Simonet WS, Ke HZ.
    Endocrinology; 2018 Jan 01; 159(1):260-271. PubMed ID: 29069393
    [Abstract] [Full Text] [Related]

  • 7. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model.
    Tian X, Jee WS, Li X, Paszty C, Ke HZ.
    Bone; 2011 Feb 01; 48(2):197-201. PubMed ID: 20850580
    [Abstract] [Full Text] [Related]

  • 8. Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.
    Ma YL, Hamang M, Lucchesi J, Bivi N, Zeng Q, Adrian MD, Raines SE, Li J, Kuhstoss SA, Obungu V, Bryant HU, Krishnan V.
    Bone; 2017 Apr 01; 97():20-28. PubMed ID: 27939957
    [Abstract] [Full Text] [Related]

  • 9. Progressive increases in bone mass and bone strength in an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody.
    Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ.
    Endocrinology; 2014 Dec 01; 155(12):4785-97. PubMed ID: 25259718
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis.
    Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C.
    J Bone Miner Res; 2009 Apr 01; 24(4):578-88. PubMed ID: 19049336
    [Abstract] [Full Text] [Related]

  • 14. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
    Iida-Klein A, Lu SS, Cosman F, Lindsay R, Dempster DW.
    Bone; 2007 Feb 01; 40(2):391-8. PubMed ID: 17056311
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Decreased osteoprogenitor proliferation precedes attenuation of cancellous bone formation in ovariectomized rats treated with sclerostin antibody.
    Boyce RW, Brown D, Felx M, Mellal N, Locher K, Pyrah I, Ominsky MS, Taylor S.
    Bone Rep; 2018 Jun 01; 8():90-94. PubMed ID: 29955626
    [Abstract] [Full Text] [Related]

  • 17. Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats.
    Suen PK, Zhu TY, Chow DH, Huang L, Zheng LZ, Qin L.
    Sci Rep; 2015 Oct 23; 5():15632. PubMed ID: 26494536
    [Abstract] [Full Text] [Related]

  • 18. Effects of Sclerostin Antibody on the Healing of Femoral Fractures in Ovariectomised Rats.
    Liu Y, Rui Y, Cheng TY, Huang S, Xu L, Meng F, Lee WY, Zhang T, Li N, Li C, Ke H, Li G.
    Calcif Tissue Int; 2016 Mar 23; 98(3):263-74. PubMed ID: 26603303
    [Abstract] [Full Text] [Related]

  • 19. Systemic administration of sclerostin monoclonal antibody accelerates fracture healing in the femoral osteotomy model of young rats.
    Feng G, Chang-Qing Z, Yi-Min C, Xiao-Lin L.
    Int Immunopharmacol; 2015 Jan 23; 24(1):7-13. PubMed ID: 25479724
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.